Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer

In recent years, Non-small cell lung cancer (NSCLC) has evolved into a prime example for precision oncology with multiple FDA-approved “precision” drugs. For the majority of NSCLC lacking targetable genetic alterations, immune checkpoint inhibition (ICI) has become standard of care in first-line tre...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2020-06, Vol.12 (6), p.1685
Main Authors: Schatz, Stefanie, Falk, Markus, Jóri, Balázs, Ramdani, Hayat O., Schmidt, Stefanie, Willing, Eva-Maria, Menon, Roopika, Groen, Harry J. M., Diehl, Linda, Kröger, Matthias, Wesseler, Claas, Griesinger, Frank, Hoffknecht, Petra, Tiemann, Markus, Heukamp, Lukas C.
Format: Article
Language:English
Subjects:
Bioinformatics
Biomarkers
Cancer therapies
Chemotherapy
Deoxyribonucleic acid
DNA
Genes
Immune checkpoint inhibitors
Immunosuppressive agents
Immunotherapy
Kinases
Laboratories
Lung cancer
Mutation
Next-generation sequencing
Non-small cell lung carcinoma
Oncology
PD-1 protein
PD-L1 protein
Precision medicine
Small cell lung carcinoma
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In recent years, Non-small cell lung cancer (NSCLC) has evolved into a prime example for precision oncology with multiple FDA-approved “precision” drugs. For the majority of NSCLC lacking targetable genetic alterations, immune checkpoint inhibition (ICI) has become standard of care in first-line treatment or beyond. PD-L1 tumor expression represents the only approved predictive biomarker for PD-L1/PD-1 checkpoint inhibition by therapeutic antibodies. Since PD-L1-negative or low-expressing tumors may also respond to ICI, additional factors are likely to contribute in addition to PD-L1 expression. Tumor mutation burden (TMB) has emerged as a potential candidate; however, it is the most complex biomarker so far and might represent a challenge for routine diagnostics. We therefore established a hybrid capture (HC) next-generation sequencing (NGS) assay that covers all oncogenic driver alterations as well as TMB and validated TMB values by correlation with the assay (F1CDx) used for the CheckMate 227 study. Results of the first consecutive 417 patients analyzed in a routine clinical setting are presented. Data show that fast reliable comprehensive diagnostics including TMB and targetable alterations are obtained with a short turn-around time. Thus, even complex biomarkers can easily be implemented in routine practice to optimize treatment decisions for advanced NSCLC.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12061685